Orexigen (OREX) Posts Narrower-than-Expected Loss in Q3

Zacks Equity Research
Updated
0

Orexigen Therapeutics, Inc. OREX reported a loss of $1.01 per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of $2.13 but wider than the year-ago loss of 86 cents.

FindTheCompany | Graphiq

Quarterly revenues came in at approximately $7 million, down from to $10 million in the year-ago quarter, which included an anniversary milestone earned from Takeda Pharmaceutical Company Limited TKPYY. Revenues were also missed the Zacks Consensus Estimate of $16 million.

Quarterly Detail

Orexigen recorded Contrave sales of $5.3 million in the U.S., following its Aug 2016 acquisition of the U.S. rights to the product. Royalties on U.S. sales of Contrave were $0.9 million. The company also received collaborative income of $0.9 million.

As per IMS Health data, Contrave scrips were down 13.6% sequentially to 165,141 in the third quarter of 2016.

While R&D expenses declined 40.4% from the year-ago period to $5.3 million, general and administrative expenses were up 190% to $35.1 million.

Meanwhile, Orexigen's Central and Eastern European (CEE) partner, Valeant Pharmaceuticals International, Inc. VRX, launched Mysimba (EU brand name for Contrave) in five countries. Valeant expects to launch the drug in six additional CEE countries by 2016 end, and in Greece and Cyprus in the first quarter of 2017.

Guidance

Orexigen expects cash operating expenses of $160–$180 million in 2016. Contrave U.S. net sales are envisioned in the range of $47–$52 million.

While R&D spend is projected in the range of $44–$49 million, the company anticipates spending $80– $90 million on sales and marketing. General and administrative expenses are estimated in the range of $36–$41 million.

Total annual cash operating expenses are expected in the range of $180–$200 million during the 2017–2019 period. This includes annual sales and marketing expenses of about $80–$100 million. External R&D expenses are projected to be $15–$20 million per year in 2016 and 2017, and an average of $50 million a year from 2018 through 2021, doe to costs related to the cardiovascular outcomes study.

Orexigen expects to achieve profitability in 2019, with U.S. sales in the range of $160 million–$260 million.

Contrave’s market share, which was 6% in Aug and Sep 2016, is expected to be mostly flat in the fourth quarter, followed by growth in the first half of 2017. Annual market share growth is expected in the range of 2–6% during the 2017–2019 timeframe.

OREXIGEN THERAP Price, Consensus and EPS Surprise

 

OREXIGEN THERAP Price, Consensus and EPS Surprise | OREXIGEN THERAP Quote

Zacks Rank & Key Picks

Orexigen carries a Zacks Rank #3 (Hold). Infinity Pharmaceuticals, Inc. INFI is a better- ranked stock in the healthcare sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Infinity’s loss estimates narrowed from $3.84 to $3.79 for 2016 but remained unchanged for 2017 over the last 60 days. The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67.62%.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
OREXIGEN THERAP (OREX): Free Stock Analysis Report
 
INFINITY PHARMA (INFI): Free Stock Analysis Report
 
VALEANT PHARMA (VRX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement

Recommended Stories

  • Dow Jones Falls As Donald Trump Stock Craters; Cathie Wood Buys This Stock Amid 51% Plunge

    The Dow Jones fell as Elon Musk made a Tesla move. The Donald Trump stock sank on the stock market today. Cathie Wood bought a diving stock.

  • Trump Media stock tanks on move to issue millions of shares

    Trump Media stock slid as much as 16% on Monday after the parent company of Donald Trump's social media platform, Truth Social, filed to issue more than 21 million shares.

  • 4 Oversold Stocks to Buy Right Now

    Here are four stocks to buy now that could offer investors upside in the short and long term.

  • Wall Street Selloff Goes Global Amid US Rate Angst: Markets Wrap

    (Bloomberg) -- A selloff on Wall Street went global as investors grappled with the threat of higher-for-longer interest rates, China’s sluggish economy and an Israeli counter-strike. Most Read from BloombergBeyond the Ivies: Surprise Winners in the List of Colleges With the Highest ROIIran’s Attack on Israel Sparks Race to Avert a Full-Blown WarApple Faces Worst iPhone Slump Since Covid as Rivals RiseIsrael Versus Iran — What All-Out War Could Look LikeTesla Executive Baglino Leaves as Musk Lose

  • Nvidia Reveals 8 'Secrets' For When To Sell Stocks. No. 2 Is Key.

    As top growth stocks like Nvidia test key moving averages, keep in mind these proven rules for when to sell stocks.

  • Tesla layoffs hit high performers, some departments slashed, sources say

    Tesla management told employees Monday that the recent layoffs -- which gutted some departments by 20% and even hit high performers -- were largely due to poor financial performance, a source familiar with the matter told TechCrunch. The layoffs were announced to staff just a week before Tesla is scheduled to report its first-quarter earnings. The move comes as Tesla has seen its profit margin narrow over the past several quarters, the result of an EV price war that has persisted for at least a year.

  • Elon Musk Agrees With Jamie Dimon's Warning Of Political Polarization 'Creating Risks That Could Eclipse Anything Since World War II'

    JP Morgan Chase & Co. (NYSE:JPM) CEO Jamie Dimon's annual shareholder letter is a moment investors await to understand the thinking of one of the world's most influential bankers. While there has been speculation of Dimon entering politics, with him even gaining the support of billionaire hedge fund manager Bill Ackman to run for president, JP Morgan shared in a statement that "Jamie has no plans to run for office" and that "he is very happy in his current role." That has not stopped him from oc

  • Xiaomi’s Success Means More Trouble for Battered China EV Stocks

    (Bloomberg) -- Xiaomi Corp.’s roaring entry into the electric vehicle market is dimming the recovery outlook for China’s beaten down auto startups.Most Read from BloombergBeyond the Ivies: Surprise Winners in the List of Colleges With the Highest ROIIran’s Attack on Israel Sparks Race to Avert a Full-Blown WarApple Faces Worst iPhone Slump Since Covid as Rivals RiseIsrael Versus Iran — What All-Out War Could Look LikeTesla Executive Baglino Leaves as Musk Loses Another Top DeputyHype around the

  • Not-So-Happy Meal: $20 Wages Has Burger Joints In This State All Heated

    California fast-food employees started earning a minimum of $20 an hour in April. Thanks to a new law, which went into effect earlier this month, California chain restaurants with at least 60 locations nationwide have to pay their employees more. For smaller restaurants, the minimum wage continues to be the statewide bottom of $16 an hour. The largest publicly-traded fast-food companies include McDonald’s Corp (NYSE:MCD); Starbucks Corp (NASDAQ:SBUX); Yum! Brands, Inc. (NYSE:YUM), which owns Tac

  • Trump Media tumbles 18% after taking the first step towards unlocking early insider stock sales

    The Truth Social parent company has filed to allow insiders, such as former president Donald Trump, to sell their stake in the company.